Table 1.

Intracellular triphosphates and total phosphates of d4T (1 μM), ZDV (0.1 μM), and ribothymidine (1 μM)a

PBMCs and phosphateIntracellular nucleosides (pmol/106 cells)
Healthy volunteersHIV patients
Resting PBMCs
 d4TTP0.005 ± 0.0020.008 ± 0.005*
 d4T total phosphates0.056 ± 0.0160.083 ± 0.0463*
 ZDVTP0.001 ± 0.0010.002 ± 0.002
 ZDV total phosphates0.032 ± 0.0240.081 ± 0.059*
 ThdTP0.021 ± 0.0170.020 ± 0.021
 Thd total phosphates0.162 ± 0.0520.232 ± 0.233
PHA-stimulated PBMCs
 d4TTP0.023 ± 0.0130.020 ± 0.013
 d4T total phosphates0.638 ± 0.3130.343 ± 0.204*
 ZDVTP0.054 ± 0.0570.020 ± 0.011
 ZDV total phosphates4.043 ± 2.1722.796 ± 2.824
 ThdTP0.198 ± 0.1570.082 ± 0.060
 Thd total phosphates7.553 ± 5.4862.843 ± 2.691*
  • a Following 24-h ex vivo incubation in resting and PHA (10 μg/ml; 72 h)-stimulated PBMCs from healthy volunteers and HIV patients. Data are expressed as mean ± standard deviations (n ≥ 6). The data were analyzed by the Mann Whitney U test. ∗, significance between healthy volunteers and HIV patients (P < 0.05). Thd, ribothymidine.